信号传导子及转录激活子-6、前列腺特异抗原在前列腺癌中的表达及意义  

Expression and significance of signal transducer and activator of transcription 6 and prostate-specific antigen proteins in prostatic carcinoma

作　　者：陈荣生[1] 罗冬娇[2] 陈立[1] 童夏生[3] 陈豪[4] 王恩智[5] 

机构地区：[1]台州市中西医结合医院附属浙江中医药大学第一临床医学泌尿外科 [2]杭州师范大学钱江学院医学系 [3]浙江台州市中西医结合医院附属浙江中医药大学第一临床医学儿科 [4]台州市中西医结合医院附属浙江中医药大学第一临床医学病理科 [5]台州市中西医结合医院附属浙江中医药大学第一临床医学检验科

出　　处：《中国临床药理学与治疗学》2009年第9期1018-1022,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的:观察信号传导子及转录激活子(STAT)-6和前列腺特异抗原(PSA)在前列腺癌中的表达,探讨前列腺癌的发病机制和早期诊断方法。方法:20例前列腺癌和36例良性前列腺增生患者均来自2005年1月-2008年5月的住院手术者,免疫组化法测定前列腺组织STAT-6和PSA蛋白的表达,电化学发光法测定血清总PSA(tPSA)及游离PSA(fPSA),彩色多普勒超声测量前列腺体积(PV),计算f/t比值和前列腺特异抗原密度(PSAD)。结果:前列腺癌组前列腺组织的STAT-6和PSA蛋白的表达水平(OD值分别为0.24±0.08和0.31±0.09)显著高于良性前列腺增生组(OD值分别为0.12±0.06和0.20±0.07)(P<0.01)。前列腺癌组血清tPSA及fPSA的含量和PSAD值[分别为(43±26)、(3.8±2.2)ng/mL和(0.88±0.66)ng.mL-1.cm-3]显著高于良性前列腺增生组[分别为(6±4)、(1.2±0.8)ng/mL和0.12±0.09)ng.mL-1.cm-3]。两组之间f/t比值和PV值[分别为(0.14±0.10)、(61±35)cm3;(0.31±0.48)、(47±24)cm3]比较差异无统计学意义(均P>0.05)。结论:STAT-6和PSA可能参与了前列腺癌的形成过程,血清tP-SA、fPSA、PSAD可作为前列腺癌(PCa)筛查良好的指标。AIM： To observe the expressions of signal transducer and activator of transcription（STAT）-6 and prostate-specific antigen（PSA） proteins in prostatic carcinoma,and approach the pathogenesis and early diagnosis methods of prostatic carcinoma.METHODS： All patients were operated during January 2005 to May 2008 including 20 cases of prostatic carcinoma and 36 cases of benign prostatic hyperplasia.The expressions of STAT-6 and PSA proteins were detected by immunohistochemical methods in prostate tissue.The concentration of totall PSA（tPSA） and free PSA（fPSA） in serum were detected by electrochemiluminescence.The prostate volume was measured by color doppler ultrasound.The ratio of f/t value and prostate specific antigen density（PSAD） were calculated.RESULTS： The expressions of STAT-6 and PSA protein were significantly higher in prostatic carcinoma group（Optical Density： 0.24±0.08 and 0.31±0.09,respectively）than those in benign prostatic hyperplasia group（Optical Density： 0.12±0.06 and 0.20±0.07,respectively）（all P〈0.01）.The concentrations of tPSA and fPSA in serum and PSAD were significantly higher in prostatic carcinoma group [（43±26） ng/mL,（3.8±2.2） ng/mL and（0.88±0.66） ng·mL^-1·cm^-3,respectively] than those in benign prostatic hyperplasia group[（6±4） ng/mL,（1.2±0.8） ng/mL and（0.12±0.09） ng·mL^-1·cm^-3,respectively]（all P〈0.01）.There were no statistically differences in the f/t value and prostate volume between prostatic carcinoma group[（0.14±0.10）,（61±35） cm3,respectively] and benign prostatic hyperplasia group（0.31±0.48,47±24 cm3,respectively）（all P〉0.05）.CONCLUSION： STAT-6 and PSA may participate in the development of prostatic carcinoma.The concentrations of tPSA and fPSA in serum and PSAD can be applied as effective screening targets for prostatic carcinoma diagnosis.

关 键 词：前列腺癌 信号传导子及转录激活子 前列腺特异抗原 良性前列腺增生 

分 类 号：R965.2[医药卫生—药理学]